Cancer Suppression by Lymphocytes Activated by Cancer-Mediated Exosomes: an In Vitro Study

Year 2022, Volume: 5 Issue: 2, 187 - 199, 15.08.2022

Aysegul Yılmaz , Irmak Ferah Okkay , Ali Taghizadehghalehjoughi

https://doi.org/10.38001/ijlsb.1069055

Abstract

Although exosomes were first described as cellular waste in the late 1980s, their role in cellular communication has been revealed by recent studies. In addition to components such as DNA, RNA, and protein, it is thought that it may also be associated with the immune system, as it contains tetraspanins such as CD9, CD81, and major histocompatibility complex (MHC) molecules. Therefore, it has been seen as a new source for immunotherapy. Immunotherapy is one of the methods used for colon cancer, which is one of the most common and deadly cancers, where traditional treatments are insufficient. In our study, we first performed exosome isolation from the CaCo-2 cell line, then lymphocyte (T lymphocyte) activation by the exosome. Then, we counted the activated lymphocytes (10,000, 20,000, 40,000, and 80,000 cells) and applied them to the CaCo-2 cell line in vitro. After 48 hours, we performed viability (MTT), antioxidant (TAC), oxidant (TOS) and lactate dehydrogenase (LDH) analyzes. Exosome characterization was demonstrated with TEM, SEM, and AFM images. According to our results, it was seen that the lymphocytes activated by exosomes act at similar rates with the lymphocytes activated by IL-2. In the groups given 80,000 cells, a significant decrease was observed in the viability and antioxidant level of the cancer line, while an increase in oxidant and lactate levels was observed. The tumor-suppressive properties of exosomes obtained from immune cells have been demonstrated in the literature. We have successfully produced this study with our own experience and knowledge of the literature. We have successfully produced this study with our own experience and knowledge of the literature.

Keywords

Exosomes, immunotherapy, isolation, T lymphocyte

Project Number

TDK-2021-8949

References

• Zhang, Y., et al., Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci, 2019. 9: p. 19.
• Zhou, X., et al., The function and clinical application of extracellular vesicles in innate immune regulation. Cell Mol Immunol, 2020. 17(4): p. 323-334.
• Barros, F.M., et al., Exosomes and Immune Response in Cancer: Friends or Foes? Front Immunol, 2018. 9: p. 730.
• Utsugi-Kobukai, S., et al., MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett, 2003. 89(2-3): p. 125-31.
• Li, X., et al., Role of exosomes in the immune microenvironment of ovarian cancer. Oncol Lett, 2021. 21(5): p. 377.
• Rialdi, A., et al., The RNA Exosome Syncs IAV-RNAPII Transcription to Promote Viral Ribogenesis and Infectivity. Cell, 2017. 169(4): p. 679-692 e14.
• Majer, O., et al., UNC93B1 recruits syntenin-1 to dampen TLR7 signalling and prevent autoimmunity. Nature, 2019. 575(7782): p. 366-370.
• Wolfers, J., et al., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med, 2001. 7(3): p. 297-303.
• Wu, F., et al., Exosomes increased angiogenesis in papillary thyroid cancer microenvironment. Endocr Relat Cancer, 2019. 26(5): p. 525-538.
• Li, X.B., et al., Role of exosomes in immune regulation. J Cell Mol Med, 2006. 10(2): p. 364-75.
• Borst, J., et al., CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol, 2018. 18(10): p. 635-647.
• Wang, Z.X., et al., Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol, 2014. 20(4): p. 1095-106.
• Taghizadehghalehjoughi, A., A. Hacimuftuoglu, and A. Yilmaz, Na+ channel blocker enhances metformin effects on neuroblastoma cell line. Medicine Science, 2019. 8(3): p. 636-40.
• YILMAZ, A., et al., Investigation of Aloe Vera Barbadensis Miller Leaf Extract Effects On Glutamate and Glyphosate Induced Toxicity: In Vitro Study. Journal of Anatolian Environmental and Animal Sciences, 2021. 6(3): p. 376 - 381.
• Liu, Y., et al., Exosomes and Their Role in Cancer Progression. Front Oncol, 2021. 11: p. 639159.
• Whiteside, T.L., Tumor-Derived Exosomes and Their Role in Cancer Progression. Adv Clin Chem, 2016. 74: p. 103-41.
• Cohen, E.E.W., et al., The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer, 2019. 7(1): p. 184.
• Ganesh, K., et al., Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol, 2019. 16(6): p. 361-375.
• Waldman, A.D., J.M. Fritz, and M.J. Lenardo, A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol, 2020. 20(11): p. 651-668.
• Oldford, S.A., et al., Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol, 2006. 18(11): p. 1591-602.
• Dieu-Nosjean, M.C., et al., Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol, 2008. 26(27): p. 4410-7.
• Gonzalez, H., C. Hagerling, and Z. Werb, Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev, 2018. 32(19-20): p. 1267-1284.
• Raskov, H., et al., Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer, 2021. 124(2): p. 359-367.
• Ross, S.H. and D.A. Cantrell, Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol, 2018. 36: p. 411-433.
• Reem, G.H. and N.H. Yeh, Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science, 1984. 225(4660): p. 429-30.
• Kasahara, T., et al., Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol, 1983. 130(4): p. 1784-9.